Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic Update

20 Feb 2007 07:00

Embargoed: 0700hrs, 20 February 2007

Akers Biosciences, Inc. Strategic Update

Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, point of care screening and testing products, is pleased to announce that Thomas A. Nicolette has agreed to take an executive position on the board as its new President. Moving Nicolette into an executive role, from his previous non-executive position, marks the transition of the Company from its scientific research and development roots to capitalising on its product portfolio through an emphasis on sales and marketing.

Over the last four years the Company has invested significant resources in the creation and development of platform technologies for rapid testing and screening procedures, and is now in a position to advance the market penetration of its products. Over the last twelve months the Company has made two strategic acquisitions which give it direct access to the US Military and other end users of its BreathScan, BreathAlcohol Check and LegalLimit brands of disposable alcohol testing units. Another important product for the Company is the proprietary PIFA Heparin/PF4 Rapid Assay which is currently being distributed throughout Canada, North America and, imminently, Europe. PIFA H/ PF4 is now in use or evaluation in over 780 hospitals in the US and this number is increasing on a weekly basis, whilst existing hospital customers are moving towards regular re-orders.

In order to facilitate this scale-up in production, as previously announced, the Company is designing a 43,000 sq ft manufacturing facility in Puerto Rico, expected to be on stream by November 2007, affording a substantial reduction in cost of goods manufactured as well as supply chain efficiencies.

Dr Raymond Akers, Chief Executive Officer, commented,

"Tom's appointment as President is extremely beneficial as he will now be able to give his attention, on a full time basis, to working alongside me to extract the full financial potential of our products. Having invested so much of our time and resources in creating our product line, now is the time make the transition to sales and marketing."

Thomas A. Nicolette, President, said,

"Having personally built up a number of technology based companies and progressed them into their commercial phases, I recognise that the Company is poised to enter its commercial phase fully. I am confident that my commercial experience coupled with Dr Akers' intimate understanding of the diagnostic marketplace will put us in a strong position to take advantage of the efforts of the last four years."

Enquiries:Dr. Ray Akers Chief Executive Officer, Akers 001 856 848 8698 Biosciences, Inc.

Thomas Nicolette President, Akers Biosciences, Inc. 001 856 848 8698 Ben Simons Hansard Group 020 7245 1100

Thomas A. Nicolette comes from a blue-chip business background having served as Chairman, President and Chief Executive Officer of several public companies in the USA. The largest, KNOGO Corporation, was a NYSE listed multi-national headquartered on Long Island, NY with subsidiaries, dealers and manufacturing facilities in 32 countries around the world. KNOGO, recognised as the founder of the Electronic Article Surveillance (EAS) anti-shoplifting industry, was sold to Sensormatic Electronics Corporation and is now part of Tyco International, the largest Electronic Security provider in the world.

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring rapid healthcare information directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

AKERS BIOSCIENCES INC
Date   Source Headline
8th May 20181:00 pmRNSHolding(s) in Company
27th Apr 20182:05 pmRNSSecond Price Monitoring Extn
27th Apr 20182:00 pmRNSPrice Monitoring Extension
26th Apr 20187:00 amRNSDirectorate Change
13th Apr 20185:45 pmRNSIssue of Equity
12th Apr 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
6th Apr 20184:30 pmRNSIssue of Equity
3rd Apr 201811:05 amRNSFinal Results
28th Mar 20184:20 pmRNSNotice of Fiscal Year 2017 Earnings - Rescheduled
26th Mar 20187:01 amRNSDistribution Agreement with Diagnostica Stago
26th Mar 20187:00 amRNSIssue of Equity
16th Mar 20184:00 pmRNSIssue of Equity
15th Mar 20185:30 pmRNSNotice of Results
9th Mar 20186:29 pmRNSIssue of Equity
2nd Mar 20185:15 pmRNSIssue of Equity
16th Feb 20185:45 pmRNSIssue of Equity
14th Feb 20185:30 pmRNSHoldings in Company
9th Feb 20186:00 pmRNSIssue of Equity
2nd Feb 20184:42 pmRNSIssue of Equity
26th Jan 20187:00 amRNSIssue of Equity
22nd Jan 20184:27 pmRNSHoldings in Company
19th Jan 20183:35 pmRNSIssue of Equity
16th Jan 20186:20 pmRNSIssue of Equity
15th Jan 20187:00 amRNSUpdate RE Admission of Shares
12th Jan 20187:00 amRNSIssue of Equity
5th Jan 20186:29 pmRNSIssue of Equity
4th Jan 20184:45 pmRNSHoldings in Company
27th Dec 20172:01 pmRNSIssue of Equity
22nd Dec 20177:00 amRNSClosing of Public Offering
19th Dec 20177:00 amRNSIssue of Equity
18th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
15th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
14th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
11th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
8th Dec 20173:30 pmRNSFurther IP Protection for Akers Wellness Line
1st Dec 20172:00 pmRNSForm 8K Filing
27th Nov 20177:00 amRNSForm S-1 Registration Statement
15th Nov 20177:00 amRNS3rd Quarter Results
14th Nov 20177:00 amRNSNew UK Channel for Rapid Alcohol Breathalyzer
13th Nov 20172:00 pmRNSNotice of Results
8th Nov 20171:59 pmRNSIssue of Equity
20th Oct 20177:00 amRNSPDMR Shareholding and Issue of Equity
19th Oct 20174:20 pmRNSDirector/PDMR Shareholding
13th Oct 20172:35 pmRNSWarrant Amendment and Exercise
7th Sep 20177:00 amRNSAppointment of U.S. VP of Sales & Distribution
15th Aug 20177:00 amRNSHalf-year Report
11th Aug 20177:00 amRNSIssue of Equity
8th Aug 20177:00 amRNSResult of AGM
3rd Aug 20174:30 pmRNSTrading Update and Notice of Q2 Results
20th Jul 201711:10 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.